Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

Xu, C.F.; Xue, Z.; Bing, N.; King, K.S.; McCann, L.A.; de Souza, P.L.; Goodman, V.L.; Spraggs, C.F.; Mooser, V.E.; Pandite, L.N.

doi:10.1093/annonc/mds249

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

Details

Request a copy

Serval ID

serval:BIB_968AFCD6236B

Type

Article: article from journal or magazin.

Publication sub-type

Letter (letter): Communication to the publisher.

Collection

Publications

Institution

UNIL/CHUV

Title

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

Journal

Annals of Oncology

Author(s)

Xu C.F., Xue Z., Bing N., King K.S., McCann L.A., de Souza P.L., Goodman V.L., Spraggs C.F., Mooser V.E., Pandite L.N.

ISSN

1569-8041 (Electronic)

ISSN-L

0923-7534

Publication state

Published

Issued date

2012

Volume

23

Number

9

Pages

2470-2471

Language

english

Notes

Publication types: Letter ; Research Support, Non-U.S. Gov't

Keywords

ATP-Binding Cassette Transporters/genetics, Alanine Transaminase/blood, Anticholesteremic Agents/adverse effects, Anticholesteremic Agents/pharmacology, Antineoplastic Agents/adverse effects, Antineoplastic Agents/pharmacology, Clinical Trials as Topic, Drug Interactions, Drug-Induced Liver Injury/epidemiology, Drug-Induced Liver Injury/genetics, Humans, Hypercholesterolemia/blood, Hypercholesterolemia/drug therapy, Incidence, Neoplasm Proteins/genetics, Neoplasms/blood, Neoplasms/drug therapy, Polymorphism, Single Nucleotide, Pyrimidines/adverse effects, Pyrimidines/pharmacology, Reference Values, Simvastatin/adverse effects, Simvastatin/pharmacology, Sulfonamides/adverse effects, Sulfonamides/pharmacology

OAI-PMH

oai:serval.unil.ch:BIB_968AFCD6236B

DOI

10.1093/annonc/mds249

Pubmed

22918879

Web of science

000308017000039

Open Access

Yes

Create date

10/01/2013 11:23